Globus Medical (NYSE:GMED) shares dipped today despite fourth-quarter results that came in ahead of the consensus forecast.
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Globus Medical (GMED – Research Report), Glaukos ...
Globus Medical started 2025 on a solid note, but a deal for loss-making Nevro creates some discomfort among investors. Read ...
Globus Medical Inc. (NYSE:GMED), a leading medical device company specializing in musculoskeletal disorders, has been making waves in the healthcare sector with its recent acquisition of Nevro Corp ...
The company currently has its sales operations distributed across 51 counties worldwide. GMED is a #3 (Hold) on the Zacks Rank, with a VGM Score of A. Momentum investors should take note of this ...
Wells Fargo analyst Vik Chopra lowered the firm’s price target on Globus Medical (GMED) to $93 from $95 and keeps an Overweight rating on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback